Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-895 plus ruxolitinib in myelofibrosis
MOH_2022-10-26_012143Phase 2Completed
- Sponsor
- Telios Pharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TL-895 and ruxolitinib in myelofibrosis (MF) (3 arms), sponsored by Telios Pharma. Primary endpoints: Recommended phase 2 dose and Spleen volume response at week 24. Started Jul 2022; status: completed.
02
Drugs
TL-895ruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2022-10-26_012143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-26_012143.